Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera, after Pfizer last week made an offer for the company.
In this article
Denmark’s Novo Nordisk
said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera
, after Pfizer
in September made an offer for the company.
Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
Pfizer fa causa a Novo Nordisk sull’acquisizione di Metsera. “Controfferta viola accordi”
Guerra de opa en el adelgazamiento: Novo Nordisk supera a Pfizer con su oferta por Metsera
Novo Nordisk gatecrashes Pfizer deal with $9bn bid for Metsera
Pfizer lleva a los tribunales la guerra de opa con Novo Nordisk por la ‘start-up’ de moda en el adelgazamiento
Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid
Battle for obesity biotech Metsera heats up as Pfizer sues to block rival bid
The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies…
Pfizer said it would pay $86.25 per share in cash, a premium of 3.69% to Metsera's Friday close.
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs
La società danese propone il pagamento in contanti di 62,20 dollari per azione, rispetto ai 56,50 dollari della precedente offerta
Pfizer said Friday it filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations.
Accettata l'offerta rivista e migliorata di Pfizer da 10 miliardi di dollari che entra nel mercato dei farmaci contro l'obesità
